Skip to main content
NCBI home page
The Journal of Experimental Medicine logoLink to The Journal of Experimental Medicine
. 1969 Jan 31;129(2):315–331. doi: 10.1084/jem.129.2.315

THE INHIBITION OF PLASMIN, PLASMA KALLIKREIN, PLASMA PERMEABILITY FACTOR, AND THE C'1r SUBCOMPONENT OF THE FIRST COMPONENT OF COMPLEMENT BY SERUM C'1 ESTERASE INHIBITOR

Oscar D Ratnoff 1, Jack Pensky 1, Derek Ogston 1, George B Naff 1
PMCID: PMC2138601  PMID: 4178758

Abstract

The fraction of human serum designated as C'1 esterase inhibitor is known to inhibit the action of C'1 esterase, a plasma kallikrein, and PF/Dil, an enzyme in plasma enhancing cutaneous vascular permeability. In the present study, C'1 esterase inhibitor has been found to block the actions of plasmin and the C'1r subcomponent of the first component of complement, and to retard the generation of PF/Dil. No inhibition of blood clotting or of the generation of plasmin was demonstrable.

Full Text

The Full Text of this article is available as a PDF (1,023.4 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. ASTRUP T., MULLERTZ S. The fibrin plate method for estimating fibrinolytic activity. Arch Biochem Biophys. 1952 Oct;40(2):346–351. doi: 10.1016/0003-9861(52)90121-5. [DOI] [PubMed] [Google Scholar]
  2. DONALDSON V. H., EVANS R. R. A BIOCHEMICAL ABNORMALITY IN HEREDIATRY ANGIONEUROTIC EDEMA: ABSENCE OF SERUM INHIBITOR OF C' 1-ESTERASE. Am J Med. 1963 Jul;35:37–44. doi: 10.1016/0002-9343(63)90162-1. [DOI] [PubMed] [Google Scholar]
  3. DONALDSON V. H. Studies on the activation of a serum esterase with ether and its relationship to C'l-esterase. J Clin Invest. 1961 Apr;40:673–683. doi: 10.1172/JCI104300. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. EISEN V. EFFECT OF HEXADIMETHRINE BROMIDE ON PLASMA KININ FORMATION, HYDROLYSIS OF P-TOSYL-L-ARGININE METHYL ESTER AND FIBRINOLYSIS. Br J Pharmacol Chemother. 1964 Feb;22:87–103. doi: 10.1111/j.1476-5381.1964.tb01546.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Guest M. M., Daly B. M., Ware A. G., Seegers W. H. A STUDY OF ANTIFIBRINOLYSIN ACTIVITY IN THE PLASMAS OF VARIOUS ANIMAL SPECIES. J Clin Invest. 1948 Nov;27(6):785–792. doi: 10.1172/JCI102029. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. LANDERMAN N. S., WEBSTER M. E., BECKER E. L., RATCLIFFE H. E. Hereditary angioneurotic edema. II. Deficiency of inhibitor for serum globulin permeability factor and/or plasma kallikrein. J Allergy. 1962 Jul-Aug;33:330–341. doi: 10.1016/0021-8707(62)90032-1. [DOI] [PubMed] [Google Scholar]
  7. LEPOW I. H., NAFF G. B., TODD E. W., PENSKY J., HINZ C. F. Chromatographic resolution of the first component of human complement into three activities. J Exp Med. 1963 Jun 1;117:983–1008. doi: 10.1084/jem.117.6.983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. LEVY L. R., LEPOW I. H. Assay and properties of serum inhibitor of C'l-esterase. Proc Soc Exp Biol Med. 1959 Aug-Sep;101:608–611. doi: 10.3181/00379727-101-25034. [DOI] [PubMed] [Google Scholar]
  9. MARGOLIS J. Activation of plasma by contact with glass: evidence for a common reaction which releases plasma kinin and initiates coagulation. J Physiol. 1958 Nov 10;144(1):1–22. doi: 10.1113/jphysiol.1958.sp006082. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. MARGOLIS J., BISHOP E. A. Interrelations between different mechanisms of release of biologically active peptides from blood plasma. Nature. 1962 May 26;194:749–751. doi: 10.1038/194749a0. [DOI] [PubMed] [Google Scholar]
  11. MARKUS G., AMBRUS C. M. Selective inactivation of the plasminogen contaminant in thrombin. Nature. 1960 Nov 12;188:582–583. doi: 10.1038/188582a0. [DOI] [PubMed] [Google Scholar]
  12. MILES A. A., WILHELM D. L. Enzyme-like globulins from serum reproducing the vascular phenomena of inflammation. I. An activable permeability factor and its inhibitor in guinea-pig serum. Br J Exp Pathol. 1955 Feb;36(1):71–81. [PMC free article] [PubMed] [Google Scholar]
  13. MULLERTZ S. Formation and properties of the activator of plasminogen and of human and bovine plasmin. Biochem J. 1955 Nov;61(3):424–434. doi: 10.1042/bj0610424. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. NIEWIAROWSKI S., PROU-WARTELLE O. [Role of the contact factor (Hageman factor) in fibrinolysis]. Thromb Diath Haemorrh. 1959 Sep 1;3:593–603. [PubMed] [Google Scholar]
  15. Naff G. B., Ratnoff O. S. The enzymatic nature of C'1r. Conversion of C'1s to C'1 esterase and digestion of amino acid esters by C'1r. J Exp Med. 1968 Oct 1;128(4):571–593. doi: 10.1084/jem.128.4.571. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. PENSKY J., LEVY L. R., LEPOW I. H. Partial purification of a serum inhibitor of C'1-esterase. J Biol Chem. 1961 Jun;236:1674–1679. [PubMed] [Google Scholar]
  17. Prentice C. R., Ratnoff O. D., Breckenridge R. T. Experiments on the nature of the prothrombin-converting principle: alteration of proaccelerin by thrombin. Br J Haematol. 1967 Nov;13(6):898–914. doi: 10.1111/j.1365-2141.1967.tb08860.x. [DOI] [PubMed] [Google Scholar]
  18. RASMUSSEN P. S. Purification of thrombin by chromatography. Biochim Biophys Acta. 1955 Jan;16(1):157–158. doi: 10.1016/0006-3002(55)90194-3. [DOI] [PubMed] [Google Scholar]
  19. RATNOFF O. D., COLOPY J. E., PRITCHARD J. A. The blood-clotting mechanism during normal parturition. J Lab Clin Med. 1954 Sep;44(3):408–415. [PubMed] [Google Scholar]
  20. RATNOFF O. D., CRUM J. D. ACTIVATION OF HAGEMAN FACTOR BY SOLUTIONS OF ELLAGIC ACID. J Lab Clin Med. 1964 Mar;63:359–377. [PubMed] [Google Scholar]
  21. RATNOFF O. D., DAVIE E. W., MALLETT D. L. Studies on the action of Hageman factor: evidence that activated Hageman factor in turn activates plasma thromboplastin antecedent. J Clin Invest. 1961 May;40:803–819. doi: 10.1172/JCI104314. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. RATNOFF O. D., LEPOW I. H., PILLEMER L. The multiplicity of plasmin inhibitors in human serum, demonstrated by the effect of primary amino compounds. Bull Johns Hopkins Hosp. 1954 Apr;94(4):169–179. [PubMed] [Google Scholar]
  23. RATNOFF O. D., LEPOW I. H. Some properties of an esterase derived from preparations of the first component of complement. J Exp Med. 1957 Aug 1;106(2):327–343. doi: 10.1084/jem.106.2.327. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. RATNOFF O. D., MILES A. A. THE INDUCTION OF PERMEABILITY-INCREASING ACTIVITY IN HUMAN PLASMA BY ACTIVATED HAGEMAN FACTOR. Br J Exp Pathol. 1964 Jun;45:328–345. [PMC free article] [PubMed] [Google Scholar]
  25. REMMERT L. F., COHEN P. P. Partial purification and properties of a proteolytic enzyme of human serum. J Biol Chem. 1949 Nov;181(1):431–448. [PubMed] [Google Scholar]
  26. Ratnoff O. D. INCREASED VASCULAR PERMEABILITY INDUCED BY HUMAN PLASMIN. J Exp Med. 1965 Oct 31;122(5):905–921. doi: 10.1084/jem.122.5.905. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. SIEGELMAN A. M., CARLSON A. S., ROBERTSON T. Investigation of serum trypsin and related substances. I. The quantitative demonstration of trypsinlike activity in human blood serum by a micromethod. Arch Biochem Biophys. 1962 Apr;97:159–163. doi: 10.1016/0003-9861(62)90058-9. [DOI] [PubMed] [Google Scholar]

Articles from The Journal of Experimental Medicine are provided here courtesy of The Rockefeller University Press

RESOURCES